UPDATE 1-TABLE-GTx Q4 loss narrows; gives '07 view

Tue Feb 20, 2007 6:39am EST
 
[-] Text [+]
 (Adds 2007 outlook)
 Feb 20 (Reuters) -
                       GTX INC. (GTXI.O)
                        Latest Yr ago
                                qtr
 Loss (diluted, $/shr)     0.15   0.26
 Net loss ($ million)       4.7    7.8
 Total revenue
  ($ thousands)           4,600    646
 *Source: Reuters Estimates
 --The biopharmaceutical company said revenue for the latest
fourth quarter included recognition of the remaining deferred
revenue of $3.3 million from collaboration with Ortho Biotech
Products L. P. and collaboration income of $1.5 million from
Ipsen Ltd.
 --For the latest fourth quarter, analysts had on average
expected the company to post a loss of 35 cents a share,
excluding exceptional items, on revenue of $2.05 million,
according to Reuters Estimates.
 --GTx expects net loss of $45 million to $55 million for
2007. The outlook includes the continuation of two late-stage
Acapodene clinical trials and two mid-stage Ostarine trials
which will be initiated this year, the company said.
 (Reporting by Aditi Samajpati in Bangalore)


 
Kenneth Griffin, Founder, President and CEO, Citadel Investment Group LLC, speaks during the "Financial Recovery: When and How?" panel at the 2009 Milken Institute Global Conference in Beverly Hills, California April 27, 2009. REUTERS/Phil McCarten
Citadel enters the fray

Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies.  Full Article | Full Coverage 

Companies In This Article

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better